Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cyclobarbital→

Cyclobarbital Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
52-31-3
Molecular formula
C12H16N2O3
Molecular weight
236.27 g/mol
Drug class
Barbiturate sedative-hypnoticpositive allosteric modulator of GABAA receptors (historical)
Mechanism of action
Enhances GABA-mediated chloride-channel opening at GABAA receptors and can directly activate the channel at higher concentrations, producing central nervous system depression.
Indications / reported uses
  • Historical short-term treatment of insomnia and anxiety in countries where cyclobarbital was marketed; use has been discontinued or restricted in many jurisdictions because of dependence, overdose and respiratory-depression risk

Sources: NLM MeSH — Cyclobarbital · PubMed — Cyclobarbital barbiturate safety · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cyclobarbital Environmental Risk Assessment (ERA) (the Cyclobarbital ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.